Sort
40,608 grants matching “prostate cancer”
Laboratory of Genitourinary Cancer Pathogenesis Microscopy Core Facility
$595,655Ross Lake · Division Of Basic Sciences - Nci · ZIC · FY2021 · CA
Chemical markers of heterocyclic aromatic amines for human biomonitoring
$595,628Robert J. Turesky · University Of Minnesota · R01 · FY2015 · CA
Ionization Detail - Biologically based treatment planning for particle therapy beyond LET-RBE
$595,574Bruce Faddegon · University Of California, San Francisco · R01 · FY2025 · CA
Diagnosing clinically-significant prostate cancer in African American men: Systematic random versus MR-image-fusion guided biopsy
$595,520Inderbir Gill · University Of Southern California · R01 · FY2016 · CA
Biomaterials (Mf/Zn/F-BCPs) for osteoporosis therapy
$595,467Racquel Z Legeros · New York University · R01 · FY2011 · AR
The Impact of FUS-Mediated Brain Cancer Therapy on BBB Transport, Cytokines, and Immunocyte Trafficking
$595,395Kim Butts Pauly · Stanford University · R01 · FY2021 · CA
The roles of p53 in embryonic stem cells
$595,344Jing Huang · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA
Infrastructure Support and Pilot Tissue Collection for the CARET Biorepository
$595,342Marian L Neuhouser · Fred Hutchinson Cancer Center · U01 · FY2022 · CA
Olfactomedin 4 Suppresses Prostate Cancer Cell Growth and Metastasis via Negativ
$595,241Griffin Rodgers · National Heart, Lung, And Blood Institute · ZIA · FY2022 · HL
PSMA-PET to Guide Prostatectomy: Can PSMA-PET Appropriately Modify Surgery, Reduce Nerve Damage and Optimize Quality-of-Life?
$595,230Clinton David Bahler · Indiana University Indianapolis · R01 · FY2023 · CA
BKV and JCV vaccine development
$595,210Christopher Buck · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA
Clinical Pharmacogenetics
$595,171William Douglas Figg · Division Of Basic Sciences - Nci · ZIA · FY2011 · CA
Identify SNPs and Polymorphisms Involved in the Development of Prostate Cancer
$595,171William Douglas Figg · Division Of Basic Sciences - Nci · ZIA · FY2011 · CA
Pharmacokinetic and Pharmacodynamic Modeling of Anticancer Agents
$595,171William Douglas Figg · Division Of Basic Sciences - Nci · ZIC · FY2011 · CA
Bringing Capacity for Theranostic Dosimetry Planning to the Nuclear Medicine Clinic
$595,051Yuni K Dewaraja · University Of Michigan At Ann Arbor · R01 · FY2022 · CA
Bruker Avance III wide-bore (89-mm, 9.4T), vertical-bore 400-MHz NMR spectrometer
$595,000Richard A Komoroski · University Of Cincinnati · S10 · FY2012 · OD
Metastasis and biophysics of clusters of circulating tumor cells in the microcirculation
$594,889Mehmet Toner · Massachusetts General Hospital · U01 · FY2022 · CA
ACTIVE SURVEILLANCE BIOMARKERS FOR RECLASSIFICATION OF SMALL LOW-GRADE, LOW-STAGE T1C INDOLENT PROSTATE CANCER TUMORS
$594,869The Johns Hopkins University · · FY2013 · Department of Defense
CELL-FREE PLASMA TUMOR DNA AS A BIOMARKER FOR GUIDING PROSTATE CANCER THERAPY
$594,857The Johns Hopkins University · · FY2014 · Department of the Army
Effects of a telehealth exercise program for rural cancer survivors with cancer-related fatigue including integrated longitudinal assessments of objective physical function and fatty acid oxidation
$594,734Ryan J Marker · University Of Colorado Denver · R01 · FY2024 · CA
Identify SNPs and Polymorphisms Involved in the Development of Prostate Cancer
$594,718William Douglas Figg · Division Of Basic Sciences - Nci · ZIA · FY2009 · CA
Clinical Pharmacogenetics
$594,718William Douglas Figg · Division Of Basic Sciences - Nci · ZIA · FY2009 · CA
Development of Next-Generation Blood-to-barcode (B2B) chip for In Vivo CRISPR-Based Discovery of Metastasis Regulators
$594,619Shana O Kelley · Northwestern University · R01 · FY2024 · CA
Molecular mechanisms underlying lineage plasticity in prostate cancer
$594,606Himisha Beltran · Dana-Farber Cancer Inst · R37 · FY2020 · CA
Molecular mechanisms underlying lineage plasticity in prostate cancer
$594,606Himisha Beltran · Dana-Farber Cancer Inst · R37 · FY2022 · CA